---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-090062"
form_type: "8-K"
ticker: "TEM"
cik: "0001717115"
company_name: "Tempus AI, Inc."
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:17:28.929152+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tempus AI inks deals with AstraZeneca, Pathos for $200M data licensing, $35M fee for oncology AI model

## Summary
- AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.
- Tempus and Pathos sign Order Form: Pathos pays $200M data license fees over 3 years ($50M upfront); Tempus receives license to use model.
- Pathos may pay up to 50% of data license fees in shares of Pathos Series D Preferred Stock at its discretion.
- Tempus pays Pathos $35M in consideration for Pathos' commitments under the Pathos Master Agreement.
- Syndicate led by AstraZeneca will execute stock purchase agreement with Pathos in preferred stock financing round.

## SEC filing metadata
- accession: 0001193125-25-090062
- form_type: 8-K
- ticker: TEM
- cik: 0001717115
- company_name: Tempus AI, Inc.
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1717115/000119312525090062/0001193125-25-090062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1717115/000119312525090062/d944168d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-090062
- JSON: https://secwatch.observer/filing/0001193125-25-090062.json
- Plain text: https://secwatch.observer/filing/0001193125-25-090062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.